Drug resistance as a remarkable issue in cancer treatment is associated with inflammation which occurs through complex chemical reactions in the tumor microenvironment. Recent studies have implicated that glucocorticoids and NSAIDs are mainly useful combinations for inflammatory response modulation in chemotherapeutic protocols for cancer treatment. Immunosuppressive actions of glucocorticoids and NSAIDs are mainly mediated by the transrepression or activation regulation of inflammatory genes with different DNA-bound transcription factors including AP-1, NFAT, NF-κB, STAT and also, varying functions of COX enzymes in cancer cells. Interestingly, many investigations have proved the benefits of these anti-inflammatory agents in the quenching of multidrug resistance pathways. Numerous analyses on the ABC transporter promoters showed conserved nucleotide sequences with several DNA response elements that participate in transcriptional regulation. Furthermore, genetic variations in nucleotide sequences of membrane transporters were strongly associated with changes in these transporters' expression or function and a substantial impact on systemic drug exposure and toxicity. It appeared that several polymorphisms in MDR transporter genes especially MDR1 have influenced the regulatory mechanisms and explained differences in glucocorticoid responses.

抗药性作为癌症治疗中的一个显着问题与炎症有关，炎症是通过肿瘤微环境中的复杂化学反应发生的。最近的研究表明，糖皮质激素和 NSAIDs 是癌症治疗化疗方案中炎症反应调节的主要组合。糖皮质激素和 NSAIDs 的免疫抑制作用主要通过炎症基因的反式抑制或激活调节介导，这些基因具有不同的 DNA 结合转录因子，包括 AP-1、NFAT、NF-κB、STAT 以及癌细胞中 COX 酶的不同功能。有趣的是，许多研究已经证明了这些抗炎药在淬灭多药耐药途径方面的益处。对 ABC 转运蛋白启动子的大量分析表明，保守的核苷酸序列具有几个参与转录调控的 DNA 响应元件。此外，膜转运蛋白核苷酸序列的遗传变异与这些转运蛋白表达或功能的变化以及对全身药物暴露和毒性的重大影响密切相关。似乎 MDR 转运蛋白基因，尤其是 MDR1 中的几种多态性影响了调节机制并解释了糖皮质激素反应的差异。表达或功能以及对全身药物暴露和毒性的重大影响。似乎 MDR 转运蛋白基因，尤其是 MDR1 中的几种多态性影响了调节机制并解释了糖皮质激素反应的差异。表达或功能以及对全身药物暴露和毒性的重大影响。似乎 MDR 转运蛋白基因，尤其是 MDR1 中的几种多态性影响了调节机制并解释了糖皮质激素反应的差异。